<DOC>
	<DOCNO>NCT00393458</DOCNO>
	<brief_summary>This study design assess efficacy long-term safety 300 600 µg dos indacaterol deliver via single-dose dry-powder inhaler ( SDDPI ) patient chronic obstructive pulmonary disease ( COPD ) . Patients randomize receive either indacaterol 300 µg daily , indacaterol 600 µg daily , formoterol 12 µg twice daily , placebo .</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability Once Daily Indacaterol Chronic Obstructive Pulmonary Disease ( COPD ) Using Formoterol Twice Daily Active Control</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Male female adult ≥ 40 year , diagnosis chronic obstructive pulmonary disease ( COPD ) accord Global Initiative Chronic Obstructive Lung Disease ( GOLD ) guideline 2005 : 1 . Smoking history least 20 pack year 2 . Postbronchodilator force expiratory volume 1 second ( FEV1 ) &lt; 80 % ≥ 30 % predict normal value 3 . Postbronchodilator FEV1/FVC ( force volume capacity ) &lt; 70 % ( Post refers within 30 minute inhalation 400 μg salbutamol ) Patients hospitalize COPD exacerbation 6 week prior screen . Patients respiratory tract infection within 6 week prior screen . Patients concomitant pulmonary disease . Patients history asthma . Patients diabetes type I uncontrolled diabetes type II . Any patient lung cancer history lung cancer . Patients history certain cardiovascular comorbid condition . Other protocoldefined inclusion/exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>chronic obstructive pulmonary disease</keyword>
	<keyword>COPD</keyword>
	<keyword>indacaterol</keyword>
	<keyword>long-acting β2 agonist</keyword>
</DOC>